Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia


Received April 22, 2015; accepted July 14, 2015

ABSTRACT
Dual orexin receptor antagonists have been shown to promote sleep in various species, including humans. Emerging research indicates that selective orexin-2 receptor (OX2R) antagonists may offer specificity and a more adequate sleep profile by preserving normal sleep architecture. Here, we characterized JNJ-42847922 (5-((4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-(2-fluoro-6-(1,2,3)triazol-2-yl-phenyl)-methanone), a high-affinity/potent OX2R antagonist. JNJ-42847922 had an approximate 2-log selectivity ratio versus the human orexin-1 receptor. Ex vivo receptor binding studies demonstrated that JNJ-42847922 quickly occupied OX2R binding sites in the rat brain after oral administration and rapidly cleared from the brain. In rats, single oral administration of JNJ-42847922 (3–30 mg/kg) during the light phase dose dependently reduced the latency to non-rapid eye movement (NREM) sleep and prolonged NREM sleep time in the first 2 hours, whereas REM sleep was minimally affected. The reduced sleep onset and increased sleep duration were maintained upon 7-day repeated dosing (30 mg/kg) with JNJ-42847922, then all sleep parameters returned to baseline levels following discontinuation. Although the compound promoted sleep in wild-type mice, it had no effect in OX2R knockout mice, consistent with a specific OX2R-mediated sleep response. JNJ-42847922 did not increase dopamine release in rat nucleus accumbens or produce place preference in mice after subchronic conditioning, indicating that the compound lacks intrinsic motivational properties in contrast to zolpidem. In a single ascending dose study conducted in healthy subjects, JNJ-42847922 increased somnolence and displayed a favorable pharmacokinetic and safety profile for a sedative/hypnotic, thus emerging as a promising candidate for further clinical development for the treatment of insomnia.

Introduction
Orexin-A and orexin-B, also known as hypocretin-1 and hypocretin-2, are neuropeptides produced by perifornical and lateral hypothalamic neurons that project throughout the brain and bind two different G protein–coupled receptors, orexin-1 receptor (OX1R) and orexin-2 receptor (OX2R) (de Lecea et al., 1998; Sakurai et al., 1998). Impairment of the orexin system at the OX2R level in an inherited canine model of narcolepsy was reported 1 year after its initial discovery (Lin et al., 1999). At the same time, a narcoleptic phenotype was observed in mice lacking the gene coding for orexin, identifying orexin as a key mediator for the maintenance of wakefulness (Chemelli et al., 1999). The following year, Peyron and colleagues (2000) demonstrated that there was a near complete loss of central orexin production in human narcolepsy, as measured by orexin immunoreactivity in postmortem brain slices. The salient narcoleptic phenotype of orexin knockout (KO) mice and the altered orexin signaling in narcoleptic patients provided both genetic and clinical proof of the critical role of orexin receptors (OXRs) for sleep regulation. It was then hypothesized that pharmacological blockade of the OXRs would be a novel approach for the treatment of insomnia. Less than 10 years after the elucidation of the role of the orexin system, the
first clinical data on almorexant, a dual OXR antagonist (DORA), were disclosed and confirmed the validity of this new mechanism of action for the treatment of insomnia (Brisbare-Roch et al., 2007). Only a few years later, at least three other DORAs (SB-649868 [N-(2S)-1-(5-(4-fluorophenyl)-2-methyl-4-thiazolyl) carbonyl]-2-piperidinyl[methyl]-4-benzofuran-carboxamide], suvorexant, and filorexant) reached clinical phase II for the treatment of sleep-related disorders (reviewed in Hoyer and Jacobson, 2013). In August 2014, the U.S. Food and Drug Administration approved Belsomra (Merek, Kenilworth, NJ; suvorexant) for the treatment of primary insomnia.

Taking advantage of newly developed selective OX1R and OX2R antagonists, we dissected the contribution of each OXR and demonstrated that, in rodents, antagonism of OX2R alone was sufficient to induce and prolong sleep (Dugovic et al., 2009). In agreement with these data, Mang and colleagues (2012) reported that almorexant did not induce sleep in mice lacking the OX2R. Furthermore, we showed that the addition of OX1R blockade to OX2R antagonism elicited a dysregulation of rapid eye movement (REM) sleep by shifting the balance in favor of REM sleep at the expense of non-REM (NREM) sleep that may increase the risk of narcolepsy-like events (Dugovic et al., 2014).

Based on these preclinical data, we developed a selective OX2R antagonist with suitable drug-like properties for clinical evaluation. We optimized the compound for selectivity over the OX1R (greater than 50-fold), oral bioavailability, rapid absorption, and short half-life to avoid next-day residual effects. A separate paper describes the new OX2R antagonist JNJ-42847922 (5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrolo-2-yl)-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone) as a tracer (4 nM, specific activity 35 Ci/mmol) (Langmead et al., 2009). Cell membranes were prepared from a stable pool of human embryonic kidney 293 (HEK-293) cells transfected with the human OX2R or Chinese hamster ovary K1 (CHO-K1) cells transfected with the rat OX2R. Dilutions of test compounds were made in Dulbecco’s phosphate-buffered saline from 10 mM stocks dissolved in dimethylsulfoxide. After a 60-minute incubation at room temperature, binding reactions were filtered. The membranes were counted in a scintillation counter. Nonspecific binding was determined in the presence of 10 μM almorexant (2R)-2-[[1S]-6,7-dimethoxy-1-2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylethanalamide.

Affinities of compounds for the human or rat OX2R were measured using [3H]EMPA ([3H]-ethyl-2-([6-methoxy-pyridin-3-yl]-(toluene-2-sulfonil)-amino)-N-pyridin-3-ylmethyl-acetamide; 2 nM, specific activity 27 Ci/mmol) (Malherbe et al., 2009). Cell membranes were prepared from a stable pool of human embryonic kidney 293 (HEK-293) cells transfected with the human OX2R or Chinese hamster ovary K1 (CHO-K1) cells transfected with the rat OX2R. Dilutions of test compounds were made in Dulbecco’s phosphate-buffered saline from 10 mM stocks dissolved in dimethylsulfoxide. After a 60-minute incubation at room temperature, binding reactions were filtered. The membranes were counted in a scintillation counter. Nonspecific binding was determined in the presence of 10 μM almorexant (2R)-2-[[1S]-6,7-dimethoxy-1-2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylethanalamide.

In Vitro Radioligand Binding Assays. Human or rat OX2R binding was measured in competitive radioligand binding assays using [3H]EMPA ([3H]-ethyl-2-([6-methoxy-pyridin-3-yl]-(toluene-2-sulfonil)-amino)-N-pyridin-3-ylmethyl-acetamide; 2 nM, specific activity 27 Ci/mmol) (Malherbe et al., 2009). Cell membranes were prepared from a stable pool of human embryonic kidney 293 (HEK-293) cells transfected with the human OX2R or Chinese hamster ovary K1 (CHO-K1) cells transfected with the rat OX2R. Dilutions of test compounds were made in Dulbecco’s phosphate-buffered saline from 10 mM stocks dissolved in dimethylsulfoxide. After a 60-minute incubation at room temperature, binding reactions were filtered. The membranes were counted in a scintillation counter. Nonspecific binding was determined in the presence of 10 μM almorexant (2R)-2-[[1S]-6,7-dimethoxy-1-2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylethanalamide.

Affinities of compounds for the human or rat OX2R were measured using [3H]EMPA ([3H]-ethyl-2-([6-methoxy-pyridin-3-yl]-(toluene-2-sulfonil)-amino)-N-pyridin-3-ylmethyl-acetamide; 2 nM, specific activity 27 Ci/mmol) (Malherbe et al., 2009). Cell membranes were prepared from a stable pool of human embryonic kidney 293 (HEK-293) cells transfected with the human OX2R or Chinese hamster ovary K1 (CHO-K1) cells transfected with the rat OX2R. Dilutions of test compounds were made in Dulbecco’s phosphate-buffered saline from 10 mM stocks dissolved in dimethylsulfoxide. After a 60-minute incubation at room temperature, binding reactions were filtered. The membranes were counted in a scintillation counter. Nonspecific binding was determined in the presence of 10 μM almorexant (2R)-2-[[1S]-6,7-dimethoxy-1-2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylethanalamide.

In Vitro Functional Assays (Calcium Mobilization Assays). The selectivity of JNJ-42847922 was evaluated in a large panel of binding assays, including adenosine (A1, A2A, A3), adrenergic (a1a, a1b, a1c), angiotensin (AT1), dopamine (D1, D2), bradykinin (B2), cholecystokinin (CCKA), galanin (GAL2), melatonin (MT2A, MT2B), muscarinic (M1, M2, M3), neurotensin (NT1), neurokinin (NK1, NK2, NK3), opiate (μ, κ, δ), serotonin (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3C), somatostatin, vasopressin (V1a), norepinephrine transporter, dopamine transporter, and opioid channels (sodium, calcium, potassium, and chloride). These assays were performed by Eurofins (Celle L’Evescault, France).

In Vivo Functional Assays (Calcium Mobilization Assays). Functional antagonism of OX2R has been shown in cellular assays by monitoring changes in intracellular calcium. The human OX2R functional assay used PFSK-1 cells, which are a human neuroectodermal cell line that innately expresses the OX2R. The rat OX2R functional assay was performed using SK-N-Mc cells stably expressing the rat OX2R. Stably transfected CHO-K1 cells for the human OX1R or HEK-293 cells for the rat OX1R were used for the in vitro functional assays.

Since the intracellular calcium response is transient and not consistent with equilibrium assumptions, the assays were performed by first adding a standard EC50 dose of the OX2R agonist and calculating a pKα from inhibition of the agonist response by a dose range of the antagonists. The cells were plated in black 96-well tissue culture plates with clear bottoms at 50,000 cells/well and grown overnight at 37°C in 5% carbon dioxide (CO2). Dilutions of the antagonist were prepared in Hanks’ balanced salt solution from 10 mM dimethylsulfoxide stocks.
whereas dilutions of OX peptides (OX-A for OX1R assays, OX-B for OX2R assays) were prepared in Hank’s balanced salt solution + 0.1% bovine serum albumin. On the day of the assay, a 2 x dye-loading solution (BD Calcium Assay Kit; BD Biosciences, Franklin, NJ) was added to the cells and incubated for 45 minutes at 37°C in 5% CO2. Dilutions of the test compounds were added, and the cells were incubated at room temperature for 15 minutes. The cell plate was then transferred to the Fluorometric Imaging Plate Reader Tetra instrument (Molecular Devices, Sunnyvale, CA), which adds the OXr agonist and monitors changes in fluorescence reflecting intracellular calcium levels.

Results were calculated using GraphPad Prism. Raw data from the Fluorometric Imaging Plate Reader Tetra were exported as the difference between maximum and minimum fluorescence observed for each well. A nonlinear regression was used to determine the agonist EC50 and antagonist IC50 for each plate, then the antagonist Kp was calculated according to Cheng and Prussoff (1973).

**Ex Vivo Receptor Occupancy Assays in Rats.** Experiments were performed as previously described (Dugovic et al., 2009) in male Sprague-Dawley rats (300–400 g; Charles River Laboratories, San Diego, CA). Animals were treated orally with JNJ-42847922 or vehicle. Time and dose dependence were evaluated. The animals were euthanized using CO2 and decapitated at different time points after drug administration (n = 3 per time point or dose regimen). Brains were rapidly frozen on powdered dry ice and stored at −80°C before sectioning. Plasma samples were also collected for bioanalysis (liquid chromatography–tandem mass spectrometry) as previously described (Williams et al., 2010). Sections were analyzed for dopamine by high-performance liquid chromatography (0.3 mg/kg s.c.) as a positive control. Microdialysis samples were collected into 240 minutes postdosing into a 96-well plate containing 7.5 µL of antioxidant (0.1 M ascorbic acid, 1 mM oxalic acid, and 3 mM L-cysteine in ultra-pure water) maintained at 4°C. One hour prior to the end of the experiment (t = 180 minutes), each animal received an injection of amphetamine (0.3 mg/kg s.c.) as a positive control. Microdialysis samples were analyzed for dopamine by high-performance liquid chromatography with electrochemical detection (Eicom) as previously described (Galici et al., 2011). Following the experiment, the brains were removed and sliced to verify the probe placement.

The concentration of dopamine in each sample was calculated from the peak area of the chromatographic signal and the slope from the corresponding standard curve. The percent change from baseline value was calculated from the mean basal value of each neurotransmitter for each animal and is presented in the figures as the mean ± S.E.M. Data were graphed using GraphPad Prism, and statistical analysis was performed using unpaired t test with a significance threshold of P < 0.05.

**Conditioned Place Preference in Mice.** Experiments were conducted in male DBA/2 mice (30–35 g; Jackson Laboratory, Sacramento, CA). The conditioning apparatus consisted of two chambers, identical in size and texture, divided by a Plexiglass partition with a door that could be opened or closed. One of the chambers was decorated on all four walls and the floor with a black and white cow pattern and scented with lemon extract (200 µL; Kroger Co., Cincinnati, OH) as an olfactory cue. The other chamber was decorated on all four walls and the floor with a black and white checker pattern and the scent of almond extract (200 µL; Kroger Co.). The conditioning apparatus automatically recorded the location of the animal via a grid of photobeams (8 photobeams along its length and 4 along its width, evenly spaced). On the first day, during habituation to the apparatus, animals were placed in one of the chambers (chosen randomly) and given free access to both chambers (door open) for 30 minutes. Over the next 4 days, animals were conditioned twice a day. In the morning, animals received a treatment of vehicle and were immediately confined to the initially most preferred conditioning chamber (as determined during the habituation) with the door closed for 30 minutes. In the afternoon, animals received either JNJ-42847922 (10 mg/kg i.p.), zolpidem (10 mg/kg i.p.), or vehicle (20 or 45% hydroxypropyl β-cyclodextrin, 10 mL/kg i.p.) as a control, and were immediately confined to the opposite conditioning chamber (door closed) for 30 minutes. For historical reason, the intraperitoneal route of administration was used for this test. OX2R occupancy after administration of 10-mg/kg (i.p.) JNJ-42847922 was also determined in mice to demonstrate target engagement. Animals received the same treatment each
afternoon. As a positive control, an additional group of animals was conditioned in a similar manner, receiving saline (10 ml/kg i.p.) in the morning and amphetamine (2 mg/kg i.p.) in the afternoon. On the sixth day, animals received a test for conditioned place preference. Animals were placed in one of the chambers (chosen randomly), with the door open, and the time spent in each chamber was recorded over 15 minutes.

The time spent in the drug-paired chamber was analyzed with a two-way analysis of variance for test (comparing time during the habituation session to time during the conditioned place preference test) and group, with repeated measures on time. A Dunnett’s post-hoc test with a significance threshold of \( P < 0.05 \) was used to compare each group to the time spent by the vehicle group in the drug-paired chamber during the place preference test.

**Rotarod Test in Rats.** Male Sprague-Dawley rats (400–450 g; Harlan Laboratories) were trained on the rotarod (Stoelting, Wood Dale, IL) a day prior to testing. On the day of the experiment, JNJ-42847922, zolpidem, or vehicle (30% sulfobutyl ether β-cyclodextrin) was administered orally, and ethanol was coadministered intraperitoneally; the test was then conducted 15 minutes post-treatment. To ensure the time that the animals were able to remain on the rotating drum was recorded. For rotarod testing, the latencies were given a 60-second cutoff time. Statistical analysis was performed using a Kruskal-Wallis test with Dunnett’s multiple comparisons using a significance threshold of \( P < 0.05 \).

**Single Ascending Dose Study in Humans.** The study was conducted in accordance with the Declaration of Helsinki and approved by a local ethics committee. A double-blind, randomized, placebo-controlled, single ascending dose study was conducted at a phase 1 unit in Germany between May and August 2011. Eligible subjects were healthy males between 18 and 55 years of age without sleep apnea, heavy snoring, or regular use of sleep medications. Subjects in each cohort were randomized to receive a single dose of either JNJ-42847922, formulated as an oral suspension, or placebo. Subjects slept in the unit the evening prior to dosing, were fasted overnight, and received study drug the morning of the following day. A starting dose of 10 mg was administered to three subjects (JNJ-42847922, \( n = 2 \); placebo, \( n = 1 \)). Subsequent cohorts (\( n = 6 \) active, 3 placebo) received doses of 10, 20, 40, and 80 mg, based upon review of safety, tolerability, and plasma pharmacokinetic data for each cohort. Assessments were performed while subjects remained in the clinic at least 72 hours after dosing, as well as at a follow-up visit 1–2 weeks after dosing.

Safety assessments included collection of adverse events, physical and neurologic examinations, vital signs, 12-lead and continuous ECGs, pulse oximetry, and blood and urine safety laboratories. Venous blood samples were collected for determination of plasma JNJ-42847922 levels at various time points through 72 hours after dosing. Plasma samples were analyzed using a validated, specific, and sensitive liquid chromatography/mass spectrometry/mass spectrometry method. The Stanford Sleepiness Scale was used to collect subjects’ ratings of somnolence at 2, 8, and 12 hours after dosing.

**Chemicals.** Almorexant, EMPA, SB-674042, JNJ-10397049, and JNJ-42847922 were synthesized at Janssen Research & Development LLC (San Diego, CA). Zolpidem tartrate was obtained from Aarti Drugs Ltd. (Tarapur, Maharashtra). Peptides were obtained from Bachem (Torrance, CA).

**Results**

**JNJ-42847922 Is a Selective High-Affinity OX2R Antagonist.** JNJ-42847922 showed high-affinity binding to the human and rat OX2R, with \( pK_a \) values of 8.0 and 8.1, respectively (Table 1). The binding selectivity of JNJ-42847922 at the OX2R compared with the OX1R was substantial (approximately 2 log units). In a panel of 50 receptors, ion channels, and transporter assays, JNJ-42847922 at 1 μM had no significant affinity for any receptor/transporter/ion channel (<50% inhibition at 1 μM) other than the OX2R. The functional antagonism of JNJ-42847922 for the human or rat OX2R assessed by measuring changes in intracellular calcium in cell culture assays in response to an EC₅₀ dose of OX-A showed that the high-affinity OX2R binding of JNJ-42847922 was reflected in potent functional activity (Table 1). The \( pK_a \) values correlated well with the \( pK_a \) values for the human and rat OX2R. The binding selectivity of JNJ-42847922 at the OX2R compared with the OX1R was confirmed at the functional level (Table 1).

**JNJ-42847922 Crosses the Blood-Brain Barrier and Occupies the OX2R in Rat Brain after Oral Administration.** Time dependency and dose dependency of in vivo occupancy of OX2R assessed by ex vivo receptor binding autoradiography of \( [3H]EMPA \) in rat cortex brain tissue sections after oral dosing are shown in Fig. 2. Corresponding plasma and brain concentrations are presented in Table 2.

Orally administered JNJ-42847922 (30 mg/kg) inhibited \( [3H]EMPA \) binding to the rat cortex, indicating sufficient oral bioavailability and brain penetration. JNJ-42847922 OX2R occupancy reached maximal levels at 60 minutes (74 ± 6%), followed by a rapid decline to 40% at 4 hours and no occupancy at 24 hours (Fig. 2A). Overall, there was a strong relationship between receptor occupancy level and plasma/brain concentration, i.e., receptor occupancy levels dropped when plasma/brain levels decreased. In vivo OX1R occupancy was also determined in the same experiment to ensure selectivity for the OX2R. Oral administration of JNJ-42847922 (30 mg/kg) minimally inhibited \( [3H]SB-674042 \) binding to the rat tenia tecta, indicating low OX1R occupancy (<20%; data not shown).

For the dose-response analysis, ex vivo receptor occupancy was measured 15 minutes after dosing (Fig. 2B). This time point was the apparent time to maximum plasma drug concentration (\( t_{max} \)) of JNJ-42847922 attained after the 30-mg/kg dose (Table 2). The measured ED₅₀ dose was 3 mg/kg, and OX2R occupancy was approximately 74% at the highest dose of 60 mg/kg (Fig. 2B). The ED₅₀ dose of 3 mg/kg in this study corresponded to a calculated plasma exposure of 171 ng/ml. Occupancy of the OX1R by JNJ-42847922 was negligible (<20% at 30 mg/kg; data not shown). The unbound plasma concentration of JNJ-42847922 (rat plasma unbound fraction of 0.056) (Letavic et al., 2015) corresponding to 50% receptor occupancy in the rat was 9.58 ng/ml. In humans, JNJ-42847922 has a similar affinity for OX2R compared with rats. Therefore, based on a mean unbound plasma fraction of 0.029, the predicted total human plasma concentration for a 50% level of OX2R occupancy would be 330 ng/ml.

OX2R occupancy was also determined in mice to demonstrate target engagement (data not shown). After intraperitoneal

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In vitro binding affinity (( pK_a ) values) and in vivo ( pK_a ) values for intracellular calcium responses of JNJ-42847922 at human and rat OX1R and OX2R</strong></td>
</tr>
<tr>
<td>( pK_a )</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>hOX2R</td>
</tr>
<tr>
<td>hOX1R</td>
</tr>
<tr>
<td>rOX2R</td>
</tr>
<tr>
<td>rOX1R</td>
</tr>
</tbody>
</table>

H, human; r, rat.
injection of a 10-mg/kg dose, maximal OX2R occupancy (66 ± 17%) was observed at 30 minutes. The plasma concentration for maximal receptor occupancy was determined to be 1965 ± 142 ng/ml. JNJ-42847922 achieved greater than 40% OX2R occupancy for 1 hour; by 2 hours, there was no significant receptor occupancy for the remainder of the time course.

**JNJ-42847922 Dose-Dependently Induces and Prolongs Sleep in Rats.** Acute effects of JNJ-42847922 on sleep-wake patterns in rats were investigated during either the dark (active) phase or the light (rest) phase in two separate studies. In the first study (Letavic et al., 2015), rats were orally dosed at the onset of the dark phase (1, 3, 10, and 30 mg/kg), and in the second study (present data), rats were orally dosed at 2 hours into the light phase (3, 10, and 30 mg/kg). Based on our observation that the lowest dose tested was not effective in the dark phase (when the hypnotic activity of OXR antagonists is preferentially revealed), this dose of 1 mg/kg was not evaluated in the light phase. Oral administration of JNJ-42847922 during either the dark phase or the light phase produced a dose-dependent reduction in NREM sleep latency and an increase in NREM sleep time in the first 2 hours (dark phase effects shown in Letavic et al., 2015; light phase effects shown in Fig. 3). JNJ-42847922 displayed efficacy from the dose of 3 mg/kg onward for both sleep induction (decreased NREM sleep latency) [F(3, 21) = 11.45, P < 0.001] (Fig. 3A) and sleep promotion (increased NREM sleep time) [F(3, 21) = 7.89, P = 0.001] (Fig. 3C). Whereas the dose-response effects were more apparent during the dark phase than during the light phase, the time spent in NREM sleep was still gradually prolonged from 3 to 30 mg/kg. The increased NREM sleep time that was measured with the highest dose tested (30 mg/kg) during the light phase was the result of a prolongation of NREM bout duration (compound: 2.83 ± 0.16 minutes versus vehicle: 2.25 ± 0.14 minutes; P < 0.05 based on paired Student’s t test) with no change in the number of NREM bouts (compound: 28.9 ± 1.9 versus vehicle: 29.4 ± 2.4), suggesting an enhanced sleep consolidation. There was no significant effect on REM sleep latency or REM sleep duration at doses up to 30 mg/kg (Fig. 3, B and D). REM sleep latency was significantly reduced and REM sleep time was significantly increased only at the dose of 60 mg/kg tested during the dark phase (data not shown). Sleep architecture was preserved at all doses tested in the light phase, as indicated by the maintenance of the REM/total sleep ratio at 3 mg/kg (12.1%), 10 mg/kg (11.0%), and 30 mg/kg (10.9%) as compared with vehicle treatment (10.8%). Power spectral densities in NREM and REM sleep, an index of sleep intensity, were not altered, specifically with regard to NREM delta power (1–4 Hz) or REM theta power (4–10 Hz; data not shown). The sleep effects lasted for 2 hours following JNJ-42847922 administration during either the light phase or the dark phase. Concomitantly, the animals displayed a moderate reduction in locomotor activity and a small decrease in body temperature (data not shown).

**Sleep-Promoting Effects of JNJ-42847922 Are Maintained upon 7-Day Repeated Dosing in Rats.** At 2 hours into the light phase, animals were dosed orally on a daily basis with vehicle for 2 consecutive days, then with JNJ-42847922 (30 mg/kg) for 7 days (D1–D7) and again with vehicle for 2 consecutive recovery days. Sleep-wake patterns, locomotor activity, and body temperature were recorded daily except on D2, D3, and D6. Results are shown for the first 2 hours following the treatment (Fig. 4). The reduced sleep onset (NREM latency) [F(5, 40) = 18.70, P < 0.001] (Fig. 4A) and the increased NREM sleep duration [F(5, 40) = 32.14, P < 0.001] (Fig. 4C) were maintained upon 7-day repeated dosing with JNJ-42847922. The prolongation of NREM sleep time was due to a significant increase in NREM bout duration throughout the treatment period assessed on D1 and D7 [F(5, 40) = 3.65, P = 0.008] (Fig. 4E), whereas the number of NREM bouts was not affected (data not shown). REM sleep was only marginally affected on D4 of treatment, resulting in a small but significant reduction in REM sleep latency [F(5, 40) = 5.7, P < 0.001] (Fig. 4B) and an increase in REM sleep duration [F(5, 40) = 7.71, P < 0.001] (Fig. 4D). Power spectral analysis indicates...

**TABLE 2**

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>% OX2R RO</th>
<th>Brain Concentration (ng/ml)</th>
<th>Plasma Concentration (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.08</td>
<td>49 ± 5</td>
<td>205 ± 30</td>
<td>1119 ± 296</td>
</tr>
<tr>
<td>0.25</td>
<td>62 ± 1</td>
<td>646 ± 153</td>
<td>2330 ± 443</td>
</tr>
<tr>
<td>0.5</td>
<td>68 ± 1</td>
<td>512 ± 106</td>
<td>1844 ± 298</td>
</tr>
<tr>
<td>1</td>
<td>74 ± 6</td>
<td>1040 ± 388</td>
<td>2107 ± 109</td>
</tr>
<tr>
<td>2</td>
<td>43 ± 4</td>
<td>98 ± 9</td>
<td>378 ± 44</td>
</tr>
<tr>
<td>4</td>
<td>40 ± 4</td>
<td>42 ± 7</td>
<td>167 ± 24</td>
</tr>
<tr>
<td>6</td>
<td>23 ± 4</td>
<td>15 ± 3</td>
<td>105 ± 45</td>
</tr>
<tr>
<td>24</td>
<td>0 ± 0</td>
<td>BLLOQ</td>
<td>BLLOQ</td>
</tr>
</tbody>
</table>

BLLOQ, below the lowest level of quantification; RO, receptor occupancy.
that the increased sleep time did not impact sleep intensity as evidenced by consistent NREM delta power and REM theta power across vehicle and compound treatment days (data not shown). Concomitantly, locomotor activity was significantly diminished only during the JNJ-42847922 treatment period [F(5, 40) 6.25, P < 0.001] (Fig. 4F). The values of all sleep parameters and locomotor activity returned to control levels after discontinuation of the treatment.

**JNJ-42847922 Has No Effect on Sleep Parameters in Mice Lacking the OX2R.** First, spontaneous sleep-wake states were evaluated in two groups of OX2R KO and corresponding WT mice during a 24-hour baseline recording period, and the results are presented in Table 3. As compared with WT, OX2R KO mice spent less time in wake (174 minutes) and more time in NREM sleep (156 minutes) during the dark phase only. REM sleep amounts were slightly higher during the dark phase (68 minutes) but lower during the light phase (9 minutes). Next, the effects of JNJ-42847922 (30 mg/kg) on sleep parameters were investigated in WT and OX2R KO mice after oral administration at the onset of the dark phase (Fig. 5). In accordance with the differences observed in baseline conditions, OX2R KO mice showed a shorter NREM latency and higher amounts of NREM sleep as compared with WT following vehicle treatment. In WT mice, JNJ-42847922 displayed efficacy for both sleep induction (decreased NREM sleep latency) and sleep promotion (increased NREM sleep time) in the first 2 hours after compound administration (Fig. 5, A and C). These effects on NREM sleep in mice were similar to those observed in rats. As in rats, administration of JNJ-42847922 in WT mice had little impact on REM sleep latency and REM sleep duration (Fig. 5, E and G). In contrast, JNJ-42847922 did not affect any sleep parameters in OX2R KO mice. Specifically, there were no significant differences between compound and vehicle conditions in NREM sleep latency or duration (Fig. 5, B and D) or REM sleep latency or duration (Fig. 5, F and H). Interestingly, both the NREM latency and the NREM sleep duration were comparable in vehicle-treated OX2R KO mice and in WT mice treated with the OX2R antagonist. These results demonstrate that the mechanism of action for the sleep promotion elicited by JNJ-42847922 is mediated via the selective blockade of the OX2R.

**JNJ-42847922 Does Not Affect Dopamine Release in the Rat Nucleus Accumbens.** In vivo microdialysis was used to assess the effect of JNJ-42847922 on extracellular concentrations of dopamine in the nucleus accumbens of freely moving rats (Fig. 6A). Oral administration of 30 mg/kg JNJ-42847922 had no effect on extracellular dopamine release in rat nucleus accumbens (P > 0.05). Amphetamine, a common drug of abuse known to increase dopamine release in the nucleus accumbens, was administered as a positive control at the end of the study. Administration of amphetamine (0.3 mg/kg s.c.) increased dopamine release by approximately 300% above baseline levels (Fig. 6A).

**JNJ-42847922 Does Not Produce Place Preference in Mice after Subchronic Conditionings.** Mice were conditioned to zolpidem (10 mg/kg i.p.), JNJ-42847922 (10 mg/kg i.p.), or vehicle using a place preference model (Fig. 6B). Amphetamine (2 mg/kg i.p.) was also included as a positive control. A two-way analysis of variance revealed a significant

**Fig. 3.** Dose-response effects of JNJ-42847922 (3, 10, and 30 mg/kg p.o.) on sleep parameters during the light phase in rats. NREM latency (A), REM latency (B), NREM duration (C), and REM duration (D) were determined for the 2-hour period after compound or vehicle administration. Data are expressed in minutes and are presented as means ± S.E.M. of the same eight animals per dose. **P < 0.01 and ***P < 0.001 versus vehicle, based on one-way analysis of variance followed by Dunnett’s multiple comparison post-hoc test.
interaction between test and group [F(3,56) = 4.43, P = 0.007]. Dunnett’s post-hoc tests revealed that both the zolpidem and amphetamine groups spent significantly more time in the drug-paired chamber during the place preference test than the vehicle group (P < 0.05), indicating a place preference for these drugs. JNJ-42847922 was not significantly different

Fig. 4. Effects of 7-day repeated dosing (D1–D7) with JNJ-42847922 (30 mg/kg per day p.o.) on sleep parameters during the light phase in rats. NREM latency (A), REM latency (B), NREM duration (C) REM duration (D), NREM bout duration (E), and locomotor activity (F) were determined for the 2-hour period after compound or vehicle administration. Data are expressed in minutes except for locomotor activity (counts) and are presented as means ± S.E.M. of the same nine animals per condition. *P < 0.05, **P < 0.01, and ***P < 0.001 versus vehicle 2 (Veh2) condition, based on one-way analysis of variance followed by Dunnett’s multiple comparison post-hoc test.

TABLE 3
Basal duration of wake, NREM, and REM sleep during the light phase and dark phase in WT and OX2R KO mice
Data are the means ± S.E.M. (N = 10 WT, N = 10 OX2 KO) expressed in minutes.

<table>
<thead>
<tr>
<th></th>
<th>Wake Duration</th>
<th>NREM Duration</th>
<th>REM Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Light Phase</td>
<td>Dark Phase</td>
<td>Light Phase</td>
</tr>
<tr>
<td>OX2R WT</td>
<td>233.4 ± 12.6</td>
<td>472.5 ± 14.7</td>
<td>431.3 ± 11.6</td>
</tr>
<tr>
<td>OX2R KO</td>
<td>255.0 ± 5.8</td>
<td>408.6 ± 11.9**</td>
<td>416.2 ± 6.4</td>
</tr>
</tbody>
</table>

*P < 0.05 and **P < 0.01 versus WT based on unpaired Student’s t test.
from the vehicle group ($P = 0.4$), indicating a lack of place preference or aversion. OX2R occupancy was determined in mice after intraperitoneal administration of JNJ-42847922 to demonstrate target engagement (see above). The levels of receptor occupancy and plasma exposure values obtained after intraperitoneal administration (10 mg/kg) are similar to the values measured in rat after administration of a 30-mg/kg p.o. dose.

Fig. 5. Effects of JNJ-42847922 (30 mg/kg p.o.) on sleep parameters in WT and OX2R KO mice. NREM latency (A and B), NREM duration (C and D), REM latency (E and F), and REM duration (G and H) were determined for the 2-hour period after compound or vehicle administration. Data are expressed either in minutes (A–F) or in seconds (G and H) and are presented as means ± S.E.M. of the same number of animals (N = 7 WT; N = 5 OX2R KO) per condition. Vehicle is represented as open bar and JNJ-42847922 as closed bar. *$P < 0.05$ and **$P < 0.01$ versus vehicle, based on paired Student’s $t$ test.
JNJ-42847922 Has No Effect on Motor Coordination or on Alcohol-Induced Ataxia in Rats. The effects of JNJ-42847922 on ataxia in rats were evaluated using the rotarod apparatus. Animals were trained to stay on the rotarod apparatus for 60 seconds (i.e., acquisition criteria) for a maximum of three trials. When tested 24 hours later, JNJ-42847922 (30 mg/kg p.o.) had no effect on motor coordination in rats at a dose that induced sleep (Fig. 6C) \((P < 0.05)\).

The effects of JNJ-42847922 on alcohol-induced ataxia in rats were also evaluated using the rotarod apparatus. JNJ-42847922 (30 mg/kg p.o.) did not modify the ataxic effects of alcohol (1 g/kg i.p.), whereas zolpidem (10 mg/kg i.p.) exacerbated the effect of alcohol (Fig. 6D). These data indicate that JNJ-42847922 had no myorelaxant effect and no effect on alcohol-induced ataxia.

**Toxicology.** Toxicological studies up to 1 month in duration under good laboratory practice conditions were conducted in rats and dogs and indicate that JNJ-42847922 had a suitable safety profile to allow testing in humans. In both species, JNJ-42847922 was well tolerated in single- and multiple-dose studies of up to 1-month duration. JNJ-42847922 had no genotoxicity potential in the standard genotoxicity test battery and was well tolerated in a dog cardiovascular safety study.

JNJ-42847922 Displays a Suitable Pharmacokinetic Profile in Humans and Promotes Somnolence in a First-in-Human Trial. Plasma pharmacokinetics of JNJ-42847922 were characterized by rapid absorption followed by an apparently monophasic decline, with mean \(t_{\text{max}}\) for each dose ranging from 0.33 to 0.5 hour and a half-life of approximately 2 hours. The \(C_{\text{max}}\) and area under the curve values were dose-dependent but changed in a manner somewhat less than dose-proportional (Fig. 7; Table 4). Evidence of somnolence, the expected pharmacodynamic effect of JNJ-42847922, was apparent at all doses. Somnolence was reported as an adverse event for 22 of 26 subjects (85%) who received JNJ-42847922, compared with 3 of 13 subjects (23%) who received placebo. The incidence of somnolence appeared to be dose-dependent, reaching 100% at 40 mg (Fig. 8). The time of onset of the first somnolence adverse event ranged from 10 to 40 minutes after dosing, with a mean of 20 minutes for both actively treated and placebo subjects. Additionally, actively treated subjects in all cohorts had significantly higher Stanford Sleepiness Scale scores, reflecting greater sleepiness, compared with placebo at the first assessment time point of 2 hours after dosing (analysis of covariance with baseline as covariate, \(P = 0.023\) for 10 mg, \(P = 0.017\) for 20 mg, \(P < 0.0001\) for 40 and 80 mg). No significant treatment differences were observed at 8 and 12 hours after dosing.
There were no deaths, serious adverse events, or discontinuations due to an adverse event, and all events were considered mild or moderate in severity. Overall, 24 of 26 subjects (92%) who received JNJ-42847922 and 8 of 19 placebo-treated subjects (42%) had at least one adverse event, including somnolence. The most frequently reported adverse events other than somnolence were headache (12% for JNJ-42847922 versus 0% for placebo) and dizziness/postural dizziness (12% for JNJ-42847922 versus 8% for placebo). One subject administered 80 mg of JNJ-42847922 experienced a single brief episode of sleep paralysis (awareness of environment with inability to move, while transitioning from wakefulness to sleep) shortly after dosing. There were no clinically significant observations in any other safety evaluations for actively treated subjects.

**Discussion**

In the present report, we characterized a novel selective OX2R antagonist as a clinical candidate for the treatment of insomnia. We demonstrated that the compound had excellent in vitro affinity/potency/selectivity for the OX2R and promoted sleep after oral administration in rodent models. In healthy subjects, JNJ-42847922 displayed a favorable pharmacokinetic and safety profile as well as a strong pharmacodynamic effect.

Only a few selective OX2R antagonists have been reported in the literature. The first one to be reported was TCS OX229 [(2S)-1-(3,4-dihydro-6,7-dimethoxy-2-(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butane hydrochloride], a tetrahydroisoquinoline with moderate affinity but good selectivity for the OX2R (Hirose et al., 2003). Our evaluation of this molecule revealed poor pharmacokinetic properties and lack of target engagement after systemic administration in rodents (data not shown). A year later, we reported the synthesis of JNJ-10397049, a phenyl-dioxanyl urea (McAtee et al., 2004). JNJ-10397049 crossed the blood-brain barrier, engaged the OX2R, and induced sleep in rats after systemic administration (Dugovic et al., 2009). However, further development of that molecule was stopped due to poor drug-like properties, including low oral bioavailability, poor solubility, and cytochrome P450 interactions. EMPA, an acetamide, was disclosed by Roche in 2009 and was shown to be a highly selective molecule for OX2R (Malherbe et al., 2009). This molecule was also used as a radioligand for the OX2R. Eli Lilly has also recently reported the development of LSN2424100 [N-biphenyl-2-yl-4-fluoro-N-(1H-imidazol-2-ylmethyl) benzensulfonamide HCl], a sulfonamide (Fitch et al., 2014). Interestingly, this selective OX2R antagonist displayed antidepressant-like activity in rodents (Fitch et al., 2014). Last, MK-1064 (5'-chloro-N-[5,6-dimethoxy-2-yl)-2,2,3-triphenylpyridine-3-carboxamide) and MK-3897 [N-(5,6-dimethoxy-2-yl)-methyl]-5'-methyl-5-(thiazol-2-yl)-[2,3'-bipyridine]-4-carboxamide] were disclosed by Merck and are potential clinical candidates (Roecker et al., 2014a,b).

In the present study, we conducted an extensive preclinical characterization of this novel OX2R antagonist. In vitro, JNJ-42847922 was a high-affinity OX2R antagonist with an approximately 2-log selectivity ratio versus the OX1R. It had a remarkable intrinsic selectivity for the OX2R over a panel of receptors and enzymes. Taking advantage of the OX2R KO mice, we clearly demonstrated that the mechanism of action for the sleep-promoting effect occurred via selective blockade of OX2R. We also showed that both the reduced sleep onset and the increased sleep duration were maintained upon 7-day repeated dosing, and that upon discontinuation, there was no rebound effect on any of the sleep parameters measured.

Various DORAs have been shown to promote both NREM and REM sleep in animals and humans (Hoyer and Jacobson, 2014). Various DORAs have been shown to promote both NREM and REM sleep in animals and humans (Hoyer and Jacobson, 2014).

**TABLE 4**

<table>
<thead>
<tr>
<th>Dose</th>
<th>N</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/ml)</th>
<th>t&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>AUC&lt;sub&gt;inf&lt;/sub&gt; (ng.h/ml)</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>309 ± 74</td>
<td>0.33</td>
<td>802 ± 275</td>
<td>2.02 ± 0.26</td>
</tr>
<tr>
<td>20</td>
<td>6</td>
<td>556 ± 104</td>
<td>0.42</td>
<td>1615 ± 607</td>
<td>2.11 ± 0.47</td>
</tr>
<tr>
<td>40</td>
<td>6</td>
<td>743 ± 149</td>
<td>0.42</td>
<td>1807 ± 533</td>
<td>2.02 ± 0.30</td>
</tr>
<tr>
<td>80</td>
<td>6</td>
<td>1208 ± 291</td>
<td>0.50</td>
<td>3655 ± 1064</td>
<td>2.44 ± 0.46</td>
</tr>
</tbody>
</table>

AUC<sub>inf</sub>: area under the curve.
promotes NREM sleep, as opposed to the DORAs SB-649868 and suvorexant that have been reported to predominantly promote REM sleep (Dugovic et al., 2014; Etori et al., 2014). Importantly, specificity of OX2R antagonists may favorably preserve sleep architecture as evidenced by the maintenance of the REM/total sleep ratio with JNJ-42847922 (present study) and JNJ-10397049 (Dugovic et al., 2009) even at doses that also promote REM sleep, in contrast to several dual OX1/2R antagonists (Hoyer et al., 2013; Dugovic et al., 2014; Etori et al., 2014).

We also evaluated the potential abuse liability of this mechanism of action using neurochemistry and conditioned place preference. The neurochemistry experiment showed that JNJ-42847922 did not increase dopamine release in nucleus accumbens. In the conditioned place preference test, JNJ-42847922 did not produce place preference, unlike zolpidem, indicating that the compound lacks intrinsic motivational properties. The rotarod test was also used to assess the effect of JNJ-42847922 on motor coordination. At 30 mg/kg, a dose 10-fold higher than the minimal effective dose to induce sleep, the compound did not alter motor coordination. In addition, the compound did not potentiate the ataxic effect of alcohol in this test. This is in sharp contrast to the well known zolpidem-induced ataxia, highlighting the safety advantage of this new mechanism of action versus the traditional GABAAergic mechanism. Therefore, JNJ-42847922, similar to other OXR antagonists, promotes sleep without causing motor impairment or alcohol interaction (reviewed in Hoyer and Jacobson, 2013; Winrow and Renger, 2014).

JNJ-42847922 did show great promise as a development candidate for the treatment of insomnia. A clear, consistent, and rapid hypnotic-like effect was observed with single-dose administration of 10–80 mg in healthy subjects. JNJ-42847922 was safe and well tolerated, and had a favorable pharmacokinetic profile for a sedative/hypnotic, characterized by rapid absorption and a short half-life of approximately 2 hours. The human pharmacokinetic profile is in line with the prediction based on the pharmacokinetic properties in mouse, rat, dog, and monkey (Letavic et al., 2015). Specifically, the compound had a relatively short duration of action in all preclinical species and moderate to low bioavailability. Remarkably, the plasma concentration obtained in humans at the 20-mg dose (~550 ng/ml) is in the range of the plasma concentration required to occupy 50% of OX2R in rat brain occupancy studies (~400 ng/ml). Preliminary EEG polysonmography data obtained in a phase 1b study showed that treatment with JNJ-42847922 resulted in significant improvement in both sleep onset and total sleep duration in patients with comorbid insomnia related to major depressive disorder (http://ir.minervaneurosciences.com/). Further details will be disclosed in a future manuscript.

In conclusion, JNJ-42847922 displayed a favorable pharmacokinetic and safety profile in concert with a strong pharmacodynamic effect on sleep induction. The data indicate multiple points of differentiation from nonbenzodiazepine sedative-hypnotics such as zolpidem, as well as clear distinction on sleep architecture and achievable efficacy from DORAs such as suvorexant. Thus, JNJ-42847922 is a prototype of the selective orexin-2 receptor antagonists emerging as a promising new class of nonsedative hypnotics for further clinical development in the treatment of insomnia.
Hoyer D and Jacobson LH (2013) Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?


References


Wrote or contributed to the writing of the manuscript: Bonaventure, Halter, Dugovic.

Acknowledgments

The authors thank Dr. K. Sharp and staff at Janssen Research & Development LLC for their assistance.

Authorship Contributions

Participated in research design: Bonaventure, Chaplan, Aguilar, Lovenberg, Dugovic, Koudriakova, Ndfior.

Conducted experiments: Shelton, Yun, Nepomuceno, Sutton, Aluisio, Fraser, Lord, Shoblock, Welty.

Contributed new reagents or analytic tools: Letavic, Carruthers, Rizollo.

Performed data analysis: Dugovic, Shelton, Yun, Nepomuceno, Lord, Aluisio, Shoblock, Halter, Chaplan.

Address correspondence to: Pascal Bonaventure or Christine Dugovic, Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, CA 92121. E-mail: Pbonav1@its.jnj.com or CDugovic@its.jnj.com